TLP
PMVP icon

Tri Locum Partners’s PMV Pharmaceuticals PMVP Stock Holding History

Tri Locum Partners’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-821,384
Closed -$5.04M – 47
2023
Q3 		$5.04M Buy
821,384
+662,971
+419% +$4.56M 1.61% 23
2023
Q2 		$992K Buy
+158,413
New +$830K 0.37% 35

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Tri Locum Partners's PMVP Position: Q4 2023 in Review

Tri Locum Partners sold out of PMV Pharmaceuticals (PMVP) in Q4 2023, closing a stake of 821,384 shares — an estimated $5.04M sold.

Tri Locum Partners first reported a position in PMVP in Q2 2023 and held it in 2 quarters. The position peaked at $5.04M in Q3 2023. 98 funds tracked by Wall St. Rank hold PMVP as of Q4 2023.

  • Tri Locum Partners reported no remaining PMV Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Tri Locum Partners sold 821,384 PMV Pharmaceuticals shares in Q4 2023, an estimated $5.04M.
  • Tri Locum Partners first reported a position in PMV Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Tri Locum Partners's PMV Pharmaceuticals position peaked at $5.04M in Q3 2023.
  • 98 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2023.

Based on Tri Locum Partners's 13F filing for Q4 2023, filed 14 Feb 2024.